ARCA Historical Balance Sheet

ABIO Stock

USD 3.25 0.04 1.25%

Trend analysis of ARCA Biopharma balance sheet accounts such as Short Long Term Debt Total of 239.4 K, Other Current Liabilities of 533 K or Total Current Liabilities of 605.1 K provides information on ARCA Biopharma's total assets, liabilities, and equity, which is the actual value of ARCA Biopharma to its prevalent stockholders. By breaking down trends over time using ARCA Biopharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ARCA Biopharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ARCA Biopharma is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.

About ARCA Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of ARCA Biopharma at a specified time, usually calculated after every quarter, six months, or one year. ARCA Biopharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of ARCA Biopharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which ARCA currently owns. An asset can also be divided into two categories, current and non-current.

ARCA Biopharma Balance Sheet Chart

ARCA Biopharma Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how ARCA Biopharma uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, ARCA Biopharma's Common Stock Shares Outstanding is very stable compared to the past year. As of the 19th of April 2024, Capital Lease Obligations is likely to grow to about 255.2 K, while Total Assets are likely to drop about 34.9 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of ARCA Biopharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in ARCA Biopharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on ARCA Biopharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of ARCA Biopharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from ARCA Biopharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into ARCA Biopharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ARCA Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.At this time, ARCA Biopharma's Common Stock Shares Outstanding is very stable compared to the past year. As of the 19th of April 2024, Capital Lease Obligations is likely to grow to about 255.2 K, while Total Assets are likely to drop about 34.9 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	383K	280K	252K	239.4K
Total Assets	54.9M	43.1M	37.9M	34.9M

Short Long Term Debt Total Total Assets

ARCA Biopharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Non Currrent Assets Other	Common Stock Total Equity	Current Deferred Revenue	Other Liab
Total Assets		0.21	0.68	0.59	0.99	0.12	-0.97	-0.64	0.51	0.96	0.01	1.0	-0.06	0.72	0.24	0.54	0.78	0.62	0.26	1.0	0.07	0.24	-0.25	-0.24	-0.28	-0.24
Short Long Term Debt Total	0.21		0.02	0.18	0.19	0.99	-0.2	0.19	0.24	0.21	0.38	0.18	-0.51	0.23	0.89	0.4	-0.12	0.38	0.99	0.19	0.96	-0.87	0.67	0.87	0.83	0.87
Other Current Liab	0.68	0.02		0.93	0.69	-0.02	-0.6	-0.37	0.72	0.64	0.04	0.67	-0.09	0.24	0.07	0.84	0.5	0.88	0.01	0.7	-0.13	0.28	-0.26	-0.28	-0.26	-0.28
Total Current Liabilities	0.59	0.18	0.93		0.61	0.15	-0.49	-0.18	0.91	0.54	0.26	0.57	-0.22	0.07	0.23	0.87	0.33	0.98	0.14	0.61	-0.01	0.08	-0.03	-0.08	-0.05	-0.08
Total Stockholder Equity	0.99	0.19	0.69	0.61		0.11	-0.96	-0.6	0.51	0.97	0.01	0.98	-0.06	0.67	0.23	0.54	0.76	0.63	0.23	1.0	0.05	0.24	-0.24	-0.24	-0.28	-0.24
Property Plant And Equipment Net	0.12	0.99	-0.02	0.15	0.11		-0.11	0.29	0.2	0.12	0.43	0.09	-0.52	0.14	0.88	0.36	-0.21	0.34	0.98	0.1	0.97	-0.91	0.74	0.91	0.89	0.91
Net Debt	-0.97	-0.2	-0.6	-0.49	-0.96	-0.11		0.65	-0.39	-0.98	0.2	-0.98	0.01	-0.75	-0.24	-0.5	-0.79	-0.52	-0.25	-0.97	-0.06	-0.25	0.33	0.25	0.3	0.25
Retained Earnings	-0.64	0.19	-0.37	-0.18	-0.6	0.29	0.65		-0.13	-0.59	0.36	-0.66	-0.15	-0.8	0.02	-0.22	-0.97	-0.15	0.11	-0.63	0.27	-0.57	0.71	0.57	0.63	0.57
Accounts Payable	0.51	0.24	0.72	0.91	0.51	0.2	-0.39	-0.13		0.43	0.39	0.48	-0.23	0.02	0.29	0.74	0.25	0.91	0.17	0.51	0.02	0.0	0.07	0.0	0.02	0.0
Cash	0.96	0.21	0.64	0.54	0.97	0.12	-0.98	-0.59	0.43		-0.18	0.97	-0.04	0.69	0.26	0.54	0.75	0.57	0.25	0.98	0.07	0.23	-0.3	-0.23	-0.27	-0.23
Non Current Assets Total	0.01	0.38	0.04	0.26	0.01	0.43	0.2	0.36	0.39	-0.18		-0.05	-0.35	-0.21	0.27	0.06	-0.3	0.31	0.37	-0.04	0.41	-0.49	0.73	0.49	0.51	0.49
Cash And Short Term Investments	1.0	0.18	0.67	0.57	0.98	0.09	-0.98	-0.66	0.48	0.97	-0.05		-0.03	0.74	0.22	0.53	0.8	0.59	0.23	1.0	0.04	0.27	-0.29	-0.27	-0.31	-0.27
Net Receivables	-0.06	-0.51	-0.09	-0.22	-0.06	-0.52	0.01	-0.15	-0.23	-0.04	-0.35	-0.03		0.09	-0.49	-0.13	0.1	-0.3	-0.47	-0.05	-0.52	0.54	-0.5	-0.54	-0.55	-0.54
Common Stock Shares Outstanding	0.72	0.23	0.24	0.07	0.67	0.14	-0.75	-0.8	0.02	0.69	-0.21	0.74	0.09		0.26	0.25	0.82	0.14	0.35	0.7	0.2	0.19	-0.38	-0.19	-0.28	-0.19
Non Current Liabilities Total	0.24	0.89	0.07	0.23	0.23	0.88	-0.24	0.02	0.29	0.26	0.27	0.22	-0.49	0.26		0.42	0.04	0.4	0.87	0.23	0.83	-0.73	0.5	0.73	0.7	0.73
Other Current Assets	0.54	0.4	0.84	0.87	0.54	0.36	-0.5	-0.22	0.74	0.54	0.06	0.53	-0.13	0.25	0.42		0.33	0.91	0.37	0.56	0.22	-0.07	-0.07	0.07	0.08	0.07
Other Stockholder Equity	0.78	-0.12	0.5	0.33	0.76	-0.21	-0.79	-0.97	0.25	0.75	-0.3	0.8	0.1	0.82	0.04	0.33		0.3	-0.04	0.79	-0.22	0.54	-0.65	-0.54	-0.6	-0.54
Total Liab	0.62	0.38	0.88	0.98	0.63	0.34	-0.52	-0.15	0.91	0.57	0.31	0.59	-0.3	0.14	0.4	0.91	0.3		0.33	0.63	0.19	-0.09	0.09	0.09	0.11	0.09
Property Plant And Equipment Gross	0.26	0.99	0.01	0.14	0.23	0.98	-0.25	0.11	0.17	0.25	0.37	0.23	-0.47	0.35	0.87	0.37	-0.04	0.33		0.23	0.97	-0.83	0.63	0.83	0.79	0.83
Total Current Assets	1.0	0.19	0.7	0.61	1.0	0.1	-0.97	-0.63	0.51	0.98	-0.04	1.0	-0.05	0.7	0.23	0.56	0.79	0.63	0.23		0.05	0.26	-0.28	-0.26	-0.3	-0.26
Short Term Debt	0.07	0.96	-0.13	-0.01	0.05	0.97	-0.06	0.27	0.02	0.07	0.41	0.04	-0.52	0.2	0.83	0.22	-0.22	0.19	0.97	0.05		-0.92	0.74	0.92	0.88	0.92
Common Stock	0.24	-0.87	0.28	0.08	0.24	-0.91	-0.25	-0.57	0.0	0.23	-0.49	0.27	0.54	0.19	-0.73	-0.07	0.54	-0.09	-0.83	0.26	-0.92		-0.89	-1.0	-0.99	-1.0
Non Currrent Assets Other	-0.25	0.67	-0.26	-0.03	-0.24	0.74	0.33	0.71	0.07	-0.3	0.73	-0.29	-0.5	-0.38	0.5	-0.07	-0.65	0.09	0.63	-0.28	0.74	-0.89		0.89	0.91	0.89
Common Stock Total Equity	-0.24	0.87	-0.28	-0.08	-0.24	0.91	0.25	0.57	0.0	-0.23	0.49	-0.27	-0.54	-0.19	0.73	0.07	-0.54	0.09	0.83	-0.26	0.92	-1.0	0.89		0.99	1.0
Current Deferred Revenue	-0.28	0.83	-0.26	-0.05	-0.28	0.89	0.3	0.63	0.02	-0.27	0.51	-0.31	-0.55	-0.28	0.7	0.08	-0.6	0.11	0.79	-0.3	0.88	-0.99	0.91	0.99		0.99
Other Liab	-0.24	0.87	-0.28	-0.08	-0.24	0.91	0.25	0.57	0.0	-0.23	0.49	-0.27	-0.54	-0.19	0.73	0.07	-0.54	0.09	0.83	-0.26	0.92	-1.0	0.89	1.0	0.99

Click cells to compare fundamentals

ARCA Biopharma Account Relationship Matchups

ARCA Biopharma balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	8.5M	50.4M	54.9M	43.1M	37.9M	34.9M
Other Current Liab	508K	1.7M	2.4M	798K	561K	533.0K
Total Current Liabilities	926K	3.5M	3.5M	1.1M	637K	605.2K
Total Stockholder Equity	7.6M	46.5M	51.0M	41.7M	37.0M	22.4M
Property Plant And Equipment Net	32K	449K	485K	368K	257K	244.2K
Net Debt	(8.3M)	(48.7M)	(53.0M)	(42.2M)	(37.2M)	(35.3M)
Retained Earnings	(144.4M)	(154.2M)	(173.5M)	(183.4M)	(188.7M)	(198.2M)
Accounts Payable	418K	1.8M	1.1M	334K	362K	343.9K
Cash	8.4M	49.1M	53.4M	42.4M	37.4M	23.0M
Non Current Assets Total	56K	461K	503K	386K	269.0K	255.5K
Cash And Short Term Investments	8.4M	49.1M	53.4M	42.4M	37.4M	34.6M
Common Stock Shares Outstanding	1.3M	4.7M	13.9M	14.4M	14.4M	15.1M
Liabilities And Stockholders Equity	8.5M	50.4M	54.9M	43.1M	37.9M	34.9M
Non Current Liabilities Total	418K	409K	383K	280K	204.0K	193.8K
Other Current Assets	117K	897K	1.1M	254K	161K	153.0K
Other Stockholder Equity	152.0M	200.7M	224.5M	225.1M	225.7M	201.0M
Total Liab	926K	3.9M	3.9M	1.4M	841K	799.0K
Property Plant And Equipment Gross	32K	449K	680K	572K	469K	445.6K
Total Current Assets	8.5M	50.0M	54.4M	42.7M	37.6M	29.0M
Property Plant Equipment	10K	449K	485K	368K	331.2K	314.6K
Net Tangible Assets	7.6M	46.5M	51.0M	41.7M	47.9M	24.1M
Retained Earnings Total Equity	(131.0M)	(138.9M)	(144.4M)	(154.2M)	(138.7M)	(145.7M)
Capital Surpluse	141.3M	145.0M	152.0M	200.7M	230.8M	136.2M
Net Invested Capital	7.6M	46.5M	51.0M	41.7M	37.0M	31.5M
Net Working Capital	7.6M	46.5M	50.9M	41.6M	37.0M	31.4M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ARCA Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ARCA Biopharma's short interest history, or implied volatility extrapolated from ARCA Biopharma options trading.

Pair Trading with ARCA Biopharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ARCA Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ARCA Biopharma will appreciate offsetting losses from the drop in the long position's value.

Moving against ARCA Stock

0.85	JNJ	Johnson Johnson Financial Report 18th of July 2024	Pair Corr
0.68	PFE	Pfizer Inc Sell-off Trend	Pair Corr
0.48	KZR	Kezar Life Sciences Financial Report 9th of May 2024	Pair Corr

The ability to find closely correlated positions to ARCA Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ARCA Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ARCA Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ARCA Biopharma to buy it.

The correlation of ARCA Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ARCA Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ARCA Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ARCA Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether ARCA Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ARCA Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arca Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arca Biopharma Stock:

How To Invest In ARCA

Details

Is ARCA Stock a good investment?

Details

What is ARCA Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in ARCA Stock, please use our How to Invest in ARCA Biopharma guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for ARCA Stock analysis

When running ARCA Biopharma's price analysis, check to measure ARCA Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ARCA Biopharma is operating at the current time. Most of ARCA Biopharma's value examination focuses on studying past and present price action to predict the probability of ARCA Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ARCA Biopharma's price. Additionally, you may evaluate how the addition of ARCA Biopharma to your portfolios can decrease your overall portfolio volatility.

	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Global Correlations Find global opportunities by holding instruments from different markets
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency

Is ARCA Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ARCA Biopharma. If investors know ARCA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ARCA Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.37)

Return On Assets

(0.11)

Return On Equity

(0.14)

The market value of ARCA Biopharma is measured differently than its book value, which is the value of ARCA that is recorded on the company's balance sheet. Investors also form their own opinion of ARCA Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ARCA Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ARCA Biopharma's market value can be influenced by many factors that don't directly affect ARCA Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ARCA Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ARCA Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ARCA Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ARCA Historical Balance Sheet

About ARCA Balance Sheet Analysis

ARCA Biopharma Balance Sheet Chart

Total Assets

Total Current Liabilities

ARCA Biopharma balance sheet Correlations

ARCA Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ARCA Biopharma balance sheet Accounts

Pair Trading with ARCA Biopharma

Moving against ARCA Stock

Complementary Tools for ARCA Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Liab	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets

Other Liab	- 1.0	Common Stock
Common Stock Total Equity	- 1.0	Common Stock
Current Deferred Revenue	- 0.99	Common Stock
Cash And Short Term Investments	- 0.98	Net Debt
Cash	- 0.98	Net Debt
Other Stockholder Equity	- 0.97	Retained Earnings